PIK3CA and cancer: In the positive phase III ExteNET study, which compared 1 year of neratinib versus placebo given in the adjuvant setting after standard trastuzumab-based therapy, absolute risk reduction was associated with neratinib treatment of patients with PIK3CA-mutated or -amplified cancers, although this reduction was not statistically significant [120].